Civica Rx plans a $ 124 million sterile injection facility dedicated to the delivery of COVID-19 drugs and more


Last spring, the up-and-coming generic drug maker Civica Rx partnered with the brand new Phlow Corp. Teamed up to put US drug manufacturing “onshore” and deliver critical drugs to hospitals battling the pandemic. Now the company is planning a special facility to do just that.

Civica is donating $ 124.5 million to build a sterile injectable injection manufacturing facility in Petersburg, Virginia – part of its team with the once obscure Phlow who became famous last year for a massive government contract to manufacture COVID-19. related drugs.

Construction has already started on the 120,000 square meter facility, which is scheduled to go into operation within the next three years, Civica called (PDF file). The facility will ultimately produce 90 million vials and 50 million pre-filled syringes per year, and will focus on drugs for COVID-19 patients, as well as drugs used in emergency rooms, intensive care units, and surgeries.

TIED TOGETHER: The top 10 manufacturers in the fight against COVID-19

The facility will be equipped with single-use technology and advanced filling lines as well as temperature-controlled storage for raw materials and finished medicinal products. It will be equipped for steam sterilization as well as automated packaging and visual inspection and is “built for future growth”.

A leadership team is already in place and more hires are expected to begin this quarter, Civica said. The plant will eventually employ around 180 people.

Civica – a generic drug manufacturer founded in 2018 to combat drug shortages and the resulting price spikes – has long been striving for its own US production in one release.

It also marks Civica’s role in a wider partnership with Phlow, enlisted Early last year in an effort by the Trump administration to boost drug manufacturing in the states.

Phlow in May signed signed a $ 354 million contract with the Biomedical Advanced Research and Development Authority (BARDA) to build a generic and active pharmaceutical ingredient (API) factory in Richmond, Virginia. This deal – one of the largest ever awarded by BARDA – can be extended to 10 years for a total of 812 million US dollars. The task of Civica is to manufacture finished medicinal products in vials and syringes for its own member hospitals and the US Strategic National Stockpile.

TIED TOGETHER: Forecast 2021: A new government will take over the White House – will the “onshore” drug manufacturing movement continue to grow?

Phlow’s notoriety surge, which caused quite a stir last spring – the company’s CEO Eric Edwards previously ran the show at Kaléo, notorious for raising the price of an EpiPen competitor by 700% – followed a conversation between Edwards and Civica- Chef VanTrieste more than a year earlier. The two had started a conversation to discuss the manufacture of a generic, VanTrieste told Fierce Pharma at the time of loan notification.

Edwards “wanted to know if I would teach him the Civica,” he said. “So we brought him in to shadow us, and he learned the pharmaceutical supply chain’s over-reliance on foreign suppliers.”

TIED TOGETHER: The US is aiming for onshore drug production in response to COVID-19. Is pharma interested at all?

Phlow was one of several companies tapped last year as part of the “onshoring” production surge fueled by a pandemic that focused on the country’s reliance on foreign APIs. In May, the US International Development Finance Corporation announced a $ 765 million loan to support camera maker Kodak’s entry into generic drug production.

Questionable stock movements that led to an investigation by the House Democrats and the Securities and Exchange Commission shook Kodak’s plans, despite the company in September it’s clear now of misconduct. CEO Jim Continenza later defended his company’s handling of the loan plans and repeated Kodak’s intention to get into API creation – with or without government support.

Source link


About Author

Comments are closed.